1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsThis opportunity funds research to develop approaches to support drug development in ultra-rare pediatric and adult cancers, including molecularly-defined subsets of more common cancers.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: The FDA funds research through various extramural programs. Government research institutions and agencies may be eligible. Confirm the full requirements in the official notice before applying.
Novel Approaches to Support Therapeutic Development in Ultra-Rare Cancers is funded by Food and Drug Administration (FDA) Office of Clinical Oncology (OCE). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The Merck Stimulating Innovative Research Grant Program 2026 includes a dedicated grant topic for artificial intelligence in cell culture media and process development, offering up to EUR 150,000 per year for up to 3 years. The program accelerates innovation through collaborative research, early engagement with industry experts, and translation of novel ideas into practical solutions. In 2026, priority areas also include in-vitro models for neuroinflammatory diseases (EUR 250,000/year for 2 years) and innovative approaches to contaminated materials remediation (EUR 150,000/year for 2 years). The two-stage application process begins with non-confidential submissions, followed by deep-dive workshops where finalists collaborate with Merck scientists and managers to jointly optimize proposals. The AI-specific grant focuses on applying machine learning and AI to optimize cell culture media formulation, bioprocess parameter optimization, and manufacturing quality control.
Small Business Innovation Research Grants (SBIR R43, R44) - Hazardous Substances Remediation and Detection Program is sponsored by National Institute of Environmental Health Sciences (NIEHS) / NIH. Fosters the commercialization of novel, cost-competitive technologies, products, and devices for remediation and detection of hazardous substances in the environment. Specifically interested in proposals applying new engineering, materials science, and biotechnology approaches.
FY26 Rare Cancers Research Program (RCRP) Concept Award is sponsored by Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP). This award supports the initial exploration of highly innovative, untested, potentially ground-breaking novel concepts in rare cancers. The potential impact may be near-term or long-term but must move beyond a minor advancement and demonstrate the potential to lead to a fundamentally new strategy or approach. Must address focus areas like Biology, Preclinical Research Model, Therapy, or AI/ML Model.
NOT-OD-26-098 consolidates NIH career development awards into four parent NOFOs (KR1, KC1, KS1, KT1), eliminates the Data Management and Sharing Plan for K applications, and stops supporting K awards that let the awardee lead their own clinical trial. The RFI closes September 30, 2026; the new structure hits due dates on or after October 12, 2027.
Read articleThe AFID Infrastructure Grant program closes October 30, 2026. Awards top out at $50,000, they are reimbursable, and only a political subdivision can apply. The August round put $507,000 into 14 projects at an average of about $36,000.
Read articleCDMRP reissued the FY26 BCRP Breakthrough Award Levels 1 and 2 and the Clinical Research Extension Award on September 3, 2026, with a November 4 pre-application deadline and a November 18 full application deadline. Round one closed July 8. The arithmetic across both windows accounts for nearly the entire FY26 appropriation — which tells you what kind of second chance this is.
Read article